Table 1.
Characteristic | No Baseline CVD | Baseline CVD | ||||
---|---|---|---|---|---|---|
| ||||||
IMPACT (n = 85) | Usual Care (n = 83) | p value | IMPACT (n = 35) | Usual Care (n = 32) | p value | |
Demographic Factors | ||||||
Age (years), mean (SD) | 66.8 (6.3) | 67.8 (6.6) | .33 | 67.9 (6.9) | 67.8 (7.8) | .97 |
Male, % | 18.8 | 22.9 | .52 | 31.4 | 31.2 | .99 |
African-American†, % | 42.4 | 53.0 | .17 | 45.7 | 46.9 | .92 |
Baseline Cardiovascular Risk Factors | ||||||
Hypertension, % | 68.2 | 75.9 | .27 | 91.4 | 78.1 | .13 |
Diabetes, % | 34.1 | 34.9 | .91 | 40.0 | 43.8 | .76 |
Smoker, % | 29.4 | 41.0 | .12 | 28.6 | 31.2 | .81 |
Body-Mass Index (kg/m2), mean (SD) | 33.2 (10.0) | 30.5 (9.5) | .066 | 31.2 (9.1) | 30.3 (8.2) | .67 |
Baseline Depression Variables | ||||||
MDD only, % | 12.9 | 10.8 | .67 | 17.1 | 6.2 | .17 |
Dysthymia only, % | 36.5 | 38.6 | .78 | 37.1 | 37.5 | .98 |
MDD and Dysthymia, % | 50.6 | 50.6 | .99 | 45.7 | 56.3 | .39 |
SCL-20 score, mean (SD) (range: 0–4) | 1.4 (0.5) | 1.5 (0.5) | .17 | 1.5 (0.5) | 1.8 (0.5) | .070 |
Antidepressant Use in Past 3 Months, % | 51.8 | 48.2 | .64 | 48.6 | 59.4 | .38 |
Depression Outcomes and Care | ||||||
SCL-20 Change, mean (SD) | −0.4 (0.7) | 0.1 (0.6) | <.001 | −0.2 (0.6) | −0.1 (0.8) | .83 |
Antidepressants during the trial, % | 75.3 | 60.2 | .037 | 79.4 | 83.9 | .64 |
Psychotherapy during the trial, % | 62.4 | 14.5 | <.001 | 58.8 | 25.8 | .007 |
Note. Independent samples t tests were used to compare groups on age, baseline SCL-20, and SCL-20 change (12-month score –baseline score). All other group comparisons were made using chi-square tests. IMPACT = Improving Mood-Promoting Access to Collaborative Treatment. MDD = major depressive disorder. SCL-20 = Symptom Checklist-20.
Because only 6 (3%) patients and 4 (2%) patients fell into the Hispanic and Other categories, respectively, we created a dichotomous race variable (0 = White, Hispanic, and Other; 1 = African American).